BioCentury
ARTICLE | Company News

Columbia University, Fortress Biotech deal

January 6, 2017 9:37 PM UTC

The university granted Fortress’ newly formed Caelum Biosciences Inc. subsidiary exclusive, worldwide development and commercialization rights to CAEL-101. The chimeric fibril-reactive mAb is in Phase...